Meltem Ocak

Meltem Ocak

Auto-generated profile, based on publicly available information

Meltem Ocak

Department of Pharmaceutical Technology, Istanbul University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2015 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LKLevent Kabasakal
Levent Kabasakal
MAMohammad AbuQbeitah
Mohammad AbuQbeitah
AAAslan Aygün
Aslan Aygün
NYNami Yeyin
Nami Yeyin
MOMeltem Ocak
Meltem Ocak
TTTurkay Toklu
Turkay Toklu

1 November 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
EDemre demirci
emre demirci
OSOnur Erdem Sahin
Onur Erdem Sahin
MOMeltem Ocak
Meltem Ocak
BABurak Akovali
Burak Akovali
JNJamal Nematyazar
Jamal Nematyazar
LKLevent Kabasakal
Levent Kabasakal
Purpose 68Ga-PSMA-11 is a novel PET tracer suggested to be used for imaging of advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of 68Ga-PSMA-11, including physiological and benign variants of prostate-specific membrane antigen (PSMA) imaging. Materials and methods We carried out a retrospective analysis of 40 patients who underwent PSMA PET/computed tomography (CT) imaging and who had no evidence of residual or metastatic disease on the scans. In addition, 16 patients who underwent PSMA PET/CT imaging with any indication other than prostate cancer were included in the study to evaluate physiological uptake in the normal prostate gland. The median, minimum–maximum, and mean standardized uptake value (SUV) values were calculated for visceral organs, bone marrow and lymph nodes, and mucosal areas. Any physiological variants or benign lesions with 68Ga-PSMA-11 were also noted. Results 68Ga-PSMA-11 uptake was noted in the kidneys, parotid and submandibular glands, duodenum, small intestines, spleen, liver, and lacrimal glands, and mucosal uptake in the nasopharynx, vocal cords, pancreas, stomach, mediastinal blood pool, thyroid gland, adrenal gland, rectum, vertebral bone marrow, and testes. Celiac ganglia showed slight 68Ga-PSMA-11 uptake in 24 of 40 patients without the presence of any other pathologic lymph nodes in abdominal and pelvic areas. Variable uptake of 68Ga-PSMA-11 was observed in calcified choroid plexus, a thyroid nodule, an adrenal nodule, axillary lymph nodes and celiac ganglia, occasional osteophytes, and gallbladder. The patient group with PSMA PET/CT for indications other than prostate cancer (n=16) showed a slight radiotracer uptake in normal prostate gland (SUVmax: 5.5±1.6, range: 3.5–8.3). Conclusion This study shows normal distribution pattern, range of SUVs, and physiological variants of 68Ga-PSMA-11. In addition, several potential pitfalls were documented to prevent misinterpretations of the scan.

20 April 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LKLevent Kabasakal
Levent Kabasakal
EDemre demirci
emre demirci
MOMeltem Ocak
Meltem Ocak
Clemens DecristoforoClemens Decristoforo
Clemens Decristoforo
AAAhmet Araman
Ahmet Araman
BKBedii Kanmaz
Bedii Kanmaz

23 April 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
EDEmre Demirci
Emre Demirci
MOMeltem Ocak
Meltem Ocak
LKLevent Kabasakal
Levent Kabasakal
Clemens DecristoforoClemens Decristoforo
Clemens Decristoforo
ZTZübeyir Talat
Zübeyir Talat
BKBedii Kanmaz
Bedii Kanmaz

12 February 2021 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
NGNic M. Gillings
Nic M. Gillings
OHOlaug Hjelstuen
Olaug Hjelstuen
JBJames R. Ballinger
James R. Ballinger
MBMartin Behe
Martin Behe
Clemens DecristoforoClemens Decristoforo
Clemens Decristoforo
STSergio Todde
Sergio Todde
This guideline on current good radiopharmacy practice (cGRPP) for small-scale preparation of radiopharmaceuticals represents the view of the Radiopharmacy Committee of the European Association of Nuclear Medicine (EANM). The guideline is laid out in the format of the EU Good Manufacturing Practice (GMP) guidelines as defined in EudraLex volume 4. It is intended for non-commercial sites such as hospital radiopharmacies, nuclear medicine departments, research PET centres and in general any healthcare establishments. In the first section, general aspects which are applicable to all levels of operations are discussed. The second section discusses the preparation of small-scale radiopharmaceuticals (SSRP) using licensed generators and kits. Finally, the third section goes into the more complex preparation of SSRP from non-licensed starting materials, often requiring a purification step and sterile filtration. The intention is that the guideline will assist radiopharmacies in the preparation of diagnostic and therapeutic SSRP’s safe for human administration.

1 June 2015 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
LKLevent Kabasakal
Levent Kabasakal
EDemre demirci
emre demirci
MOMeltem Ocak
Meltem Ocak
RAReşit Akyel
Reşit Akyel
JNJamal Nematyazar
Jamal Nematyazar
AAAhmet Araman
Ahmet Araman
Purpose The aim of the study was to evaluate the diagnostic value of the prostate-specific membrane antigen (PSMA) ligand 68Ga-HBED-CC (PSMA PET/CT) in patients with prostate cancer and evaluate the value of early imaging of the pelvis. Materials and methods The files of 28 patients were retrospectively evaluated. All patients had a histopatological confirmation of prostate cancer. PSMA PET/CT images were obtained at 5 and 60 min after injection from all patients. Results Intense pathologic radiotracer uptake was observed in 23 patients (77%) at the site of primary tumour. Lymph node metastases were detected in 10 patients (36%) and bone metastases were detected in seven patients (25%). Bone scan (n=25) results revealed metastatic bone lesions in four patients, equivocal results in nine patients and normal results in 12 patients. PSMA PET/CT confirmed bone metastases in all four patients. Pathologic radiotracer uptake in PSMA PET/CT scans was observed only in one patient among those who had equivocal bone scans. PSMA PET/CT showed additional bone lesions in two patients who had a normal bone scan. When we compared early and late pelvic images we found no difference in the number of lesions detected. The maximum standardized uptake value (SUVmax) for primary tumour, lymph nodes and bone metastases was significantly higher in late images. Conclusion PSMA PET/CT imaging seems to be a valuable imaging modality for evaluation of primary prostate cancer and it seems to have potential for the detection of lymph node and bone metastases. Early images 5 min p.i. can help to better distinguish between urinary bladder (before tracer accumulation occurs) and tumour lesions.